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Context: Insulin-like growth factor-I (IGF-I) is thought to mediate many of the anabolic actions of
growth hormone (GH) and there are anecdotal reports that IGF-I is misused by elite athletes. There
is no published evidence regarding the effects of IGF-I administration on athletic performance.
Objective: To investigate the effects of IGF-I administration on body composition and physical
fitness in recreational athletes.
Design and Setting: Randomised, double-blind, placebo-controlled rhIGF-I/rhIGFBP-3 administra-
tion study at Southampton General Hospital, UK.
Participants: 56 recreational athletes (30 men, 26 women)
Intervention: Participants were randomly assigned to receive placebo, low dose rhIGF-I/rhIGFBP-3
(30mg/day) or high dose rhIGF-I/rhIGFBP-3 (60mg/day) for 28 days. Body composition (assessed by
Dual Energy X-ray Absorptiometry) and cardiorespiratory fitness (assessed by incremental tread-
mill test),weremeasuredbeforeand immediatelyafter treatment.Within-individual changesafter
treatment were analysed using paired t-tests.
Results: There were no significant changes in body fat mass or lean body mass in women or men
after administration of rhIGF-I/rhIGFBP-3 complex. There was a significant increase in maximal
oxygen consumption (VO2 max) after treatment. When women and men and low and high dose
treatment groups were combined, mean VO2max increased by approximately 7% (P! 0.001). No
significant change in VO2 max was observed in the placebo group.
Conclusions: rhIGF-I/rhIGFBP-3 administration for 28 days improves aerobic performance in rec-
reational athletes but there are no effects on body composition.
Growth hormone ismisused by athletes for its anabolicand lipolytic properties despite it appearing on the
World Anti-Doping Agency list of prohibited substances
(1). For many years there was no clear evidence that
growth hormone (GH) improves athletic performance (2),
but recent studies have demonstrated performance-en-
hancing effects of GH in athletes, particularly when com-
bined with other anabolic agents (3, 4). Insulin-like
growth factor-I (IGF-I) mediates many of the anabolic ac-
tions of GH (5) and there are reports that this peptide is
alsomisused by athletes (6). It is possible that athletes will
be tempted to exploit IGF-I as an alternative or additional
doping agent as currently there is no internationally rec-
ognized test to detect recombinant human (rh) IGF-I mis-
ISSN Print 0021-972X ISSN Online 1945-7197
Printed in USA
Copyright © 2015 by the Endocrine Society
Received April 17, 2015. Accepted June 1, 2015.
Abbreviations:
O R I G I N A L A R T I C L E
doi: 10.1210/jc.2015-1996 J Clin Endocrinol Metab press.endocrine.org/journal/jcem 1
The Endocrine Society. Downloaded from press.endocrine.org by [${individualUser.displayName}] on 08 June 2015. at 04:19 For personal use only. No other uses without permission. . All rights reserved.
use. Previous studies have shown that administration of
IGF-I, in combination with GH, has beneficial effects on
body composition in obese postmenopausal women (7)
and that rhIGF-I administration has significant effects on
body composition when administered to adults with GH
deficiency (8). There is no evidence, however, regarding
the effects of IGF-I administrationonbodycompositionor
athletic performance in healthy athletes.
We performed a randomized, double-blind, placebo-
controlled study designed to detect changes in serum bio-
markers in response to the administration of rhIGF-I com-
plexed with rhIGF binding protein-3 (rhIGFBP-3) (9). A
further aim of this study reported here was to determine
the effects of rhIGF-I/rhIGFBP-3 administration on body
composition and physical fitness in recreational athletes.
Participants and Methods
Setting and Participants
The study was performed at the Wellcome Trust Clin-
ical Research Facility (WTCRF), Southampton General
Hospital, Southampton,UK.The study received ethics ap-
proval from the Southampton and SouthWestHampshire
Research Ethics Committee and was conducted in accor-
dance with the Declaration of Helsinki and Good Clinical
Practice guidelines. The study was regulated by the Re-
search and Development Office of University Hospital
Southampton NHS Trust. The study was not defined as a
ClinicalTrial because theMedicines andHealthcare Prod-
ucts Regulatory Agency (MHRA) did not classify the
rhIGF-I/rhIGFBP-3 complex as an Investigational Medic-
inal Product.
Fifty-six healthy recreational athletes (30 men, 26
women) aged between 18 and 30 years, who engaged in
regular physical activity (two or more sessions per week),
were recruited. Athletes were recruited by poster adver-
tisement at theUniversity of Southampton School ofMed-
icine and University of Southampton sports centers. Par-
ticipants were ineligible if they were competing at elite
level, had a history of using performance-enhancing drugs
or if theywere found to be anemic at the time of screening.
Anyonewithprevious historyof endocrinopathy, diabetes
mellitus or neoplastic disease was excluded. Pregnant
women were not allowed to participate; pregnancy tests
were performed on all female volunteers prior to enrol-
ment and they were advised to use safe contraception for
the durationof the study if sexually active.All participants
provided written informed consent.
Study design
Participants were randomly assigned to receive low
dose (30mg/d) rhIGF-I/rhIGFBP-3complex,highdose (60
mg/d) rhIGF-I/rhIGFBP-3 complex or placebo. Insmed In-
corporated (Virginia, USA) provided the rhIGF-I/
rhIGFBP-3 complex (Mecasermin Rinfabate, iPLEXTM
60 mg/ml) and matching placebo. The doses used in the
studywere selected by Insmed Incorporated based on clin-
ical trial safety data and on clinical practice. Drug vials
were stored frozen at –20°C until 30 minutes prior to
injection when the required dose was allowed to thaw at
room temperature. The injection technique was demon-
strated to each volunteer prior to the first dose. Partici-
pants self-administered the drug subcutaneously with
their evening meal for 28 consecutive days. All partici-
pants were reminded by daily text message to inject the
drug and compliance was assessed by completion of a
treatmentdiaryandbycollectionof emptydrugvials at the
end of the treatment period.
Randomisation
Insmed Incorporated prepared the rhIGF-I/rhIGFBP-3
and provided placebo in identical packaging, labeled with
the allocationnumber. Insmed Incorporatedgenerated the
random allocation sequence in blocks of varying size for
men and women and University Hospital Southampton
NHSTrustPharmacy staffwere responsible fordispensing
the studymedicationaccording to the allocation sequence.
Participants and investigators were blinded to interven-
tions at all times.
Body composition assessment
Anthropometric measurements were performed and
body composition assessed before treatment (baseline)
and at the end of treatment (Day 28). Height was mea-
sured to the nearest half-centimetre using a wall-mounted
Seca 220 stadiometer (Seca, Birmingham, UK). Body
weight was measured to the nearest 0.1 kg using Seca 876
electronic scales (Seca, Birmingham, UK) with partici-
pants dressed in light clothing. Body composition was as-
sessed using dual energy X-ray Absorptiometry (Hologic
QDR-4500WDXA Scanner, Bedford, USA) according to
standardized procedures recommended by the manufac-
turer. Calibration was performed on the day of each scan.
Participants were dressed in light clothing and scan dura-
tion was approximately 10 minutes with radiation dose
approximately 0.01 millisieverts. Lean body mass and
body fat mass were analyzed using Hologic Discovery
software version 13.0.
Physical fitness assessment
Cardiopulmonary exercise (CPX) testing was per-
formed at the time of recruitment (to allow participants to
familiarize themselveswith the testing equipment andpro-
tocol), at baseline and at the end of treatment (Day 28).
Participants were asked to maintain their normal exercise
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pattern during the treatment period.Maximal aerobic ca-
pacity was measured by incremental treadmill test on a
Woodway PPS Med treadmill (Woodway, Waukesha,
USA) using the Bruce Protocol (10). Participantswere ver-
bally encouraged to continue until exhaustion. Oxygen
consumption (VO2) was recorded continuously with an
on-line gas analyzer (Cortex MetaLyser 3B, Cortex Bio-
physik GmbH, Leipzig, Germany). Breath-by-breath gas
exchange valueswere averagedover 15 second intervals to
estimate maximal oxygen consumption (VO2 max), cor-
rected for total body weight.
Statistical analyses
We based sample size calculations on predicted re-
sponses in serum biomarkers to exogenous IGF-I admin-
istration. Power calculationswere not performed for body
composition or physical fitness outcomes as there were no
pilot data onwhich to perform the necessary calculations.
Differences in baseline characteristics between treatment
groups were assessed using ANOVA. Data from partici-
pants in low and high dose treatment groups were ana-
lyzed separately and combined. Within-individual
changes between baseline and Day 28were assessed using
paired t-tests. Between-group comparisons were per-
formed using unpaired t-tests. The relationship between
change in VO2 max and baseline BodyMass Index (BMI)
was assessed using linear regression. Because body com-
position and physical fitness data were skewed and their
distribution was normalized by log transformation, all
analyseswereperformedon log-transformeddata.P" .05
was considered statistically significant. Statistical analyses
were performed using SPSS version 19 (SPSS Inc., Chi-
cago, USA) and SAS version 8 (SAS Institute Inc., Cary,
NC, USA).
Results
6 of the 62 participants screened were not randomly as-
signed to treatment because of personal reasons. DEXA
scans were not available for 5 participants because of
scheduling and technical difficulties with the equipment.
Post-treatment (Day 28) physical fitness tests were not
possible for 3 participants because of technical difficulties
with the equipment. The analysis therefore included 51
participants for body composition measurements and 53
participants for physical fitness assessment. Compliance
with treatment was greater than 99%. Table 1 shows the
baseline characteristics of the groups. The 30 male par-
ticipants comprised 29 white Europeans and 1 Asian. The
26 female participants comprised 20 white Europeans, 2
Asians, 1 African and 3 mixed race. In men, there were
significant differences at baseline between treatment
groups inmeanweight and lean bodymass. Therewere no
significant differences at baseline between treatment
Table 1. Baseline characteristics and changes in body composition and physical fitness after 28 days of rhIGF-I/
rhIGFBP-3 treatment in 56 recreational athletes. Data from low and high dose treatment groups were analysed
separately and combined. $ Data from two women (both placebo group) and three men (all high dose IGF-I group)
were excluded because of scheduling difficulties. † Data from one woman (placebo group) and two men (both
placebo group) were excluded because of technical difficulties with the equipment. * Significant difference at
baseline (P " 0.05) compared with placebo group. ** Significant difference (P " 0.05) compared with baseline.

















group (n ! 20)
Mean age (SD), years 21.9 (2.2) 21.7 (3.4) 21.4 (1.7) 21.6 (2.6) 22.0 (2.8) 21.9 (2.7) 23.2 (2.7) 22.6 (2.7)
Mean height (SD), cm 167.5 (7.7) 165.2 (2.3) 169.0 (6.6) 167.1 (5.2) 185.0 (5.8) 179.3 (10.2) 181.3 (6.2) 180.3 (8.3)
Weight, kg
Mean (SD), baseline 61.7 (7.0) 60.2 (4.9) 60.5 (7.4) 60.3 (6.1) 92.4 (16.2) 76.9 (12.0)* 80.7 (12.9)* 78.8 (12.3)*
Mean (SD), Day 28 62.2 (6.3) 60.0 (5.5) 60.4 (7.1) 60.2 (6.2) 92.3 (16.2) 77.3 (12.8) 80.8 (13.2) 79.0 (12.8)
Mean change (SD), Day 28 minus baseline 0.5 (1.0) #0.2 (1.1) #0.1 (1.1) #0.1 (1.1) #0.1 (1.5) 0.4 (0.9) 0.1 (1.9) 0.2 (1.5)
BMI, kg/m2
Mean (SD), baseline 22.0 (1.6) 22.0 (1.8) 21.2 (2.4) 21.6 (2.1) 27.0 (4.3) 23.8 (2.5) 24.6 (3.9) 24.2 (3.2)
Mean (SD), Day 28 22.2 (1.6) 21.8 (2.2) 21.1 (2.4) 21.5 (2.3) 26.9 (4.4) 23.8 (2.7) 24.6 (3.8) 24.2 (3.2)
Mean change (SD), Day 28 minus baseline 0.2 (0.3) #0.2 (0.5) #0.1 (0.4) #0.1 (0.4) #0.1 (0.6) 0 (0.3) 0 (0.6) 0 (0.5)
Fat mass, kg $
Mean (SD), baseline 17.8 (6.0) 16.5 (5.0) 16.5 (3.8) 16.5 (4.3) 17.2 (10.4) 12.3 (4.1) 15.6 (8.0) 13.7 (6.0)
Mean (SD), Day 28 17.8 (6.0) 16.3 (5.4) 16.0 (3.9) 16.1 (4.5) 17.1 (9.9) 12.5 (3.8) 15.5 (7.7) 13.7 (5.7)
Mean change (SD), Day 28 minus baseline 0 (0.7) #0.2 (1.3) #0.5 (1.8) #0.4 (1.6) #0.1 (0.9) 0.2 (1.0) #0.1 (1.2) 0 (1.1)
Lean body mass, kg $
Mean (SD), baseline 42.0 (2.9) 40.4 (3.2) 40.7 (4.2) 40.6 (3.6) 69.6 (6.4) 60.2 (7.9)* 63.7 (7.0)* 61.6 (7.5)*
Mean (SD), Day 28 42.8 (4.1) 40.4 (3.3) 41.1 (5.2) 40.7 (4.2) 69.9 (7.3) 60.5 (8.8) 63.7 (7.7) 61.8 (8.3)
Mean change (SD), Day 28 minus baseline 0.8 (1.5) 0 (1.4) 0.4 (2.0) 0.1 (1.7) 0.3 (1.6) 0.3 (1.3) 0 (1.5) 0.2 (1.4)
VO2 max, ml/min/kg †
Mean (SD), baseline 47.0 (7.5) 48.1 (8.8) 46.2 (5.6) 47.2 (7.2) 48.0 (8.3) 51.9 (12.3) 48.0 (10.6) 50.0 (11.3)
Mean (SD), Day 28 49.4 (10.3) 52.0 (5.5) 50.8 (7.3) 51.4 (6.3)** 49.8 (6.3) 54.0 (11.3) 51.9 (9.2) 53.0 (10.1)**
Mean change (SD), Day 28 minus baseline 2.4 (5.3) 3.9 (5.9) 4.6 (7.4) 4.2 (6.5) 1.8 (8.2) 2.1 (5.5) 3.9 (7.5) 3.0 (6.5)
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groups in men or women in age, height, body mass index
(BMI), fat mass or VO2 max.
Adverse events
No participant discontinued the study because of ad-
verse effects related to the study medication. Participants
in all treatment groups (9 in the high dose group, 12 in the
low dose group and 9 in the placebo group) reported local
erythema and pain at the site of subcutaneous injections;
it is likely that this was a reaction to the solvent used to
dissolve the drug and placebo. These symptomsweremild
and resolved completely after stopping treatment. Three
participants in the high dose rhIGF-I/rhIGFBP-3 group
reported increased appetite during treatment but no par-
ticipant experienced symptomatic hypoglycemia during
the study.
Effects of treatment on body composition
There were no significant changes in fat mass or lean
bodymass inwomen ormen after administration of either
rhIGF-I/rhIGFBP-3 complex or placebo (Table 1).
Effects of treatment on physical fitness
rhIGF-I/rhIGFBP-3 administration significantly in-
creasedVO2max (Figure1 andTable 1).At baseline, there
was no significant difference in mean VO2 max between
women and men (47.1 $ 7.1 mL/min/kg vs. 49.9 $ 10.5
mL/min/kg; P ! .394). There was also no significant dif-
ference at baseline between the low and high dose treat-
ment groups (50.1$ 10.7 mL/min/kg vs. 47.2$ 8.4 mL/
min/kg; P ! .432). The within-individual changes were
therefore assessed before and after combining the data
from women and men and from low and high dose treat-
ment groups. There was approximately a 7% increase in
mean VO2 max in athletes treated with rhIGF-I/
rhIGFBP-3 (P ! .001). When the treatment groups were
assessed separately, there was a 6% increase inmeanVO2
max within the low dose group (P ! .033) and 9% in-
creasewithin the high dose group (P! .020) but therewas
no significant difference in the relative increase between
the low and high dose groups (P ! .617). When women
and men were assessed separately, there was approxi-
mately a 9% increase in meanVO2maxwithin the female
rhIGF-I/rhIGFBP-3 group (P ! .013) and a 6% increase
within the male rhIGF-I/rhIGFBP-3 group (P ! .046).
There was no significant difference in the relative increase
between women and men (P ! .599). No significant
change in VO2 max was observed within the placebo
group (P! .279 in women, P! .524 in men). Men in the
placebo group were significantly heavier than in the
rhIGF-I/rhIGFBP-3 treatment group (Table 1) but there
was no significant relationship between change in VO2
max and baseline BMI (r ! 0.195, P ! .162).
Discussion
This study demonstrates the effects of rhIGF-I/rhIGFBP-3
administration on body composition and physical fitness
in 56 recreational athletes. It is the first study to demon-
strate an improvement in aerobic performance in young,
healthy participants after administration of rhIGF-I/
rhIGFBP-3, though there were no significant effects on
body composition.
We have shown that, within the group treated with
rhIGF-I/rhIGFBP-3, therewas a statistically significant in-
crease inmaximal oxygen consumption (VO2max). It has
been suggested previously that small increments in VO2
max can have an important influence on the outcome of
aerobic endurance events (11).VO2max can be improved
by physical training and it has been shown that major
factors determining the level of improvement in aerobic
fitness include the volume, intensity and frequency of
training as well as the initial level of fitness (12). Highly
trainedathletesmight seekalternativemeansof improving
Figure 1. The effects of rhIGF-I/rhIGFBP-3 administration on physical
fitness in 26 female and 30 male recreational athletes. Individual data
points are shown (squares and solid lines) along with mean $ SD
(circles and dashed lines). Intra-individual changes were assessed using
paired t-tests, after logarithmic transformation of the data. IGF-I !
rhIGF-I/rhIGFBP-3 administration (low and high dose groups
combined). Data from one woman (placebo group) and two men (both
placebo group) were excluded because of technical difficulties with the
equipment.
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VO2 max when no further improvements can be attained
through training alone, and the effects of IGF-Imay there-
fore be attractive to this population.
The mechanisms of VO2 max improvement have not
been investigated in this study. Oxygen consumption dur-
ing exercise is dependent on many factors including effi-
cient inspiration by the respiratory system, transport of
oxygen in the circulation to skeletal muscles and effective
aerobicmetabolism by skeletal muscle fibers. It is possible
that effects on the cardiovascular system contributed to
the improved aerobic performance. It has been shownpre-
viously that intravenous (IV) administration of rhIGF-I
caused an increase in cardiac output, heart rate and stroke
volume inhealthyvolunteers (13). Furthermore it hasbeen
proposed that IGF-I has a role in regulating vascular tone
through alterations in nitric oxide synthesis (14), and
changes in intramuscular (IM) blood flow could have con-
tributed to the effects on aerobic fitness. These cardiovas-
cular variables were not assessed in this study. Another
potential explanation for the improvement is that IGF-I
treatment increases respiratory muscle strength as has
been shown in a previous rhGH administration study in
abstinent anabolic steroid users, in which both maximal
oxygen uptake and mean inspiratory pressure were in-
creased after rhGH treatment (4). It has also been shown
previously that serum IGF-I concentrations are positively
correlated with hemoglobin concentrations (15). An in-
crease in hemoglobinmight explain improved aerobic per-
formance after IGF-I treatment through enhanced oxygen
delivery to exercising skeletal muscle. Hemoglobin con-
centrationswerenotmeasured inourparticipants so itwas
not possible to determine the contribution of this factor to
the improvement observed in this study. Future studies
into the effects of IGF-I on athletic performance should
include evaluation of effects on the cardiovascular, respi-
ratory and hematological systems.
The significance of the observed improvement in VO2
max to elite athletic performance is unclear; we do not
know if an elite athlete would benefit in the same way as
the recreational athletes in this study. To put these results
in the context of elite aerobic performance, a 9% improve-
ment in aerobic performance in women translates into
approximately 75 seconds gained over the course of an
elite women’s 5000 m race (the current world record time
for women in this event is 14:11.15 minutes). Race per-
formance, however, relies on several factors in addition to
VO2 max such as glycogen depletion, lactic acid accumu-
lation andbiomechanical factors. Furthermore, the effects
of IGF-I on skeletal muscle strength in athletes were not
examined in this study; future studies should investigate
the effects of IGF-I administration on variables such as
maximal strength, explosive power and sprint capacity, as
have been investigated in previous rhGH administration
studies (3). If significant improvements in these aspects of
physical performance are demonstrated, it would suggest
potential benefits of IGF-I administration to athletes in
power sports such as sprinting and weight-lifting.
The effects of rhIGF-I/rhIGFBP-3 administration on
physical fitness were not accompanied by significant
changes in fat mass or lean body mass in this study. Pre-
vious IGF-I administration studies have yielded conflict-
ing results in terms of effects on body composition, de-
pendingon thepopulation studied.One study investigated
the effects of rhGH and rhIGF-I administration in a group
of 33 obese postmenopausal women who were undertak-
ing a diet and exercise program over 12 weeks. The ad-
ministration of rhGH alone and rhGH combined with
rhIGF-I resulted in an increase in fat-free mass in these
women, while the administration of rhIGF-I alone had no
effect on fat-free mass (7). Furthermore, substantial
changes in body compositionwere observedwhen rhIGF-I
was administered to adults with GH deficiency (8) and to
adultswithGHInsensitivity Syndrome (GHIS, a condition
caused bymutations in the gene for theGH receptor) (16).
In both of these studies rhIGF-I administration was asso-
ciated with increased lean body mass and decreased adi-
posity, and the findings in the latter study were attributed
to the stimulatory effects of rhIGF-I on lipolysis and lipid
oxidation in adults withGHIS.When rhIGF-I was admin-
istered to a group of 16 healthy postmenopausal women
for one year, however, there were no changes in lean body
mass or adipose tissue after treatment (17), similar to the
results of our current study. It is possible that the positive
effects of IGF-I administration on body composition in
patientswithGHIS reflects the severe nature of their IGF-I
deficiency (18)whereas thehealthy recreational athletes in
the current study with normal endogenous IGF-I produc-
tion are less likely to respond.
This study has some limitations. First, the study in-
volved recreational rather than elite athletes because it is
not possible to administer substances that are prohibited
in sports, to elite athletes. The baseline physical fitness
levels and body composition of an elite athlete population
would be different to the athletes in the current study and
we do not know if rhIGF-I/rhIGFBP-3 administration
would have the same effect on an elite athlete as on a
recreational athlete. Second, athletes may be misusing
rhIGF-I alone or rhIGF-I in combination with rhGH,
rather than the rhIGF-I/rhIGFBP-3 complex used in this
study, and the effects on body composition and physical
fitness may differ in those scenarios. The rhIGF-I/
rhIGFBP-3 complex (Mecasermin Rinfabate) was admin-
istered in this study because of its longer serum half-life
and lower risk of side effects such as hypoglycemia, com-
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pared with rhIGF-I alone (19). The drug is a recombinant
protein complex of rhIGF-I and rhIGFBP-3, combined
noncovalently in equimolar proportions. This forms a ter-
nary complex with endogenous acid-labile subunit (ALS)
and maintains rhIGF-I in a bound form in the circulation.
There are no confirmed cases of elite athletes obtaining
and misusing rhIGF-I/rhIGFBP-3, but it would seem an
attractive anabolic agent with lower risk of side effects,
compared with either rhIGF-I alone or insulin. Third, we
do not know the doses of IGF-I that are being misused by
elite athletes nor the typical duration of treatment. It is
likely that thedrugwouldbe taken for a longerperiod than
the 28 days employed in this study and it is possible that
prolonged administration could lead to more marked
changes in body composition as well as physical fitness.
In conclusion, this study demonstrates that 28 days of
rhIGF-I/rhIGFBP-3 administration improves aerobic fit-
ness but has no effect on body fat or lean body mass in
recreational athletes. The significance of this improve-
ment in elite athletes requires further investigation, as do
the mechanisms underlying the benefits on aerobic per-
formance. The results of this study support the inclusion
of IGF-I on the WADA list of prohibited substances and
highlight the need to develop methods for detecting IGF-I
misuse.
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